New CAR-T therapy targets Hard-to-Treat lymphoma

NCT ID NCT05741359

Recruiting now Disease control Sponsor: Bioray Laboratories Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new treatment called BRL-201 for people with relapsed or refractory B-cell non-Hodgkin lymphoma. The therapy uses a patient's own immune cells, modified to target cancer cells, and aims to control the disease. About 12-18 adults will participate to check safety and find the best dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA,B CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA,B CELL

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital of Zhejiang University
RECRUITING

Hangzhou, Zhejiang, China

Contact
Tianjin Institute of Hematology
RECRUITING

Tianjin, Tianjin Municipality, China

Contact
Wuhan Union Hospital
RECRUITING

Wuhan, Hubei, China

Contact